Kornimate/medical-research-clean huggingface dataset:
resistance exercise training at different intensities

Conditions: Sarcopenia; Frailty; Aging

Summary: the aim of the current study, therefore, is to determine the feasibility of recruitment and adherence to resistance exercise training interventions performed at low and high loads, to volitional muscular failure, in a trial population that includes both healthy and frail older people.


Eligibility criteria:
inclusion criteria: * over age of 65 years exclusion criteria: * current participation in an exercise programme * exercise deemed unsafe by clinical team
effect of sodium-glucose cotransporter-2 inhibitors (sglt-2i) on proteinuria in nephrotic children older than 10 years

Conditions: Nephrotic Syndrome in Children

Summary: the goal of this clinical trial is to evaluate the effect of ace inhibitors and sglt-2 inhibitors on: 1. proteinuria 2. renal survival indices

this is a randomized, double blind study. patients are randomized to receive oral ace inhibitors or combined acei and sglt-2inhibitrs once daily for12 weeks.

Eligibility criteria:
inclusion criteria: * age between 10 and 18 years old, * nephrotic resistant patients, * no history of diabetes, * estimated gfr≥60ml/min/1.73m2, will be evaluated by schwartz formula, * caregivers' acceptance to be enrolled in the study. exclusion criteria: * uncontrolled urinary tract infection at screening, * blood pressure is less than 5th percentile of the same gender, age, height, * at risk of dehydration or volume depletion, * evidence of liver disease: defined by serum levels of alanine transaminase or aspartate transaminase \>2 times the upper limit of normal during screening, * history of organ transplantation, cancer, liver disease, * history of noncompliance to medical regimens or unwillingness to comply with the study protocol.
pazopanib in stage iiib/iv nsclc lung cancer after progression on first line therapy containing bevacizumab

Conditions: Lung Cancer

Summary: this is an open label phase ii trial that using the investigational anti-cancer agent, pazopanib to see whether non-squamous non-small cell lung cancer will respond to its use by decreasing the size of the tumor or stopping its growth.

this multi-centered phase ii trial will examine pazopanib stage iiib/iv non-squamous nsclc patients who have progressed on first-line therapy containing bevacizumab. treatment should continue until disease progression, unacceptable toxicity, study withdrawal, or death. patients who progress will be treated at the discretion of their physician. all patients who initiate treatment will be evaluated for disease control rate, which is the primary endpoint of this study. the primary objective is to estimate the disease control rate of pazopanib alone in patients with stage iiib/iv non-squamous nsclc who progressed while on bevacizumab. disease control rate id defined as complete (cr) + partial response (pr) + stable disease (sd) lasting greater than or equal to 12 weeks as defined by recist. secondary objectives to estimate the combined response rate (cr + pr) of pazopanib according to recist to estimate the progression free survival (defined as time of enrollment until disease progression or death) and overall survival (defined as time of enrollment until death) of patients treated with pazopanib. to evaluate the safety and tolerability of pazopanib using the national cancer institute common toxicity criteria for adverse events (nci ctcae) version 4.0 to explore potential correlations between blood biomarkers and clinical response. pazopanib is dosed continuously throughout the study. cycle lengths are identified as 21 days for purposes of the calendar. the treatment dosage and administration for participating subjects will be, pazopanib, 800 mg by mouth daily during a 21 day cycle until disease progression.

Eligibility criteria:
inclusion criteria: * age 18 or older * stage iiib (with malignant pleural or pericardial effusion or supraclavicular lymph node involvement) or stage iv nsclc * evidence of progression while on bevacizumab * patients treated for cns metastases who are asymptomatic with no requirement for steroids for 2 weeks prior to first dose of study drug exclusion criteria: * prior malignancy * clinically significant gastrointestinal abnormalities * presence of uncontrolled infection or nonhealing wound, fracture, or ulcer * history of cardiovascular conditions within the past 6 months

Keywords: pazopanib non squamous non small cell lung cancer after progress on first line therapy using bevacizumab
using chronobiology to improve lenvatinib efficacy

Conditions: Lenvatinib Treatment

Summary: the goal of this proof-of-concept clinical trial is to assess the efficacy and safety of chronobiology implementation into lenvatinib treatment regimens of thyroid cancer patients, via a mobile application. participants will use a mobile application to follow variability-based physician approved drug administration schedules.

systemic treatments for thyroid cancer have emerged in the past decade, accompanied by a deeper understanding of its underlying molecular mechanisms. among these, lenvatinib, a multi-targeted tyrosine kinase inhibitor, was approved as a monotherapy for treating locally advanced or metastatic radioactive iodine refractory differentiated thyroid cancer. despite its efficacy, lenvatinib is associated with a spectrum of adverse events (aes), including hypertension, fatigue, proteinuria, and gastrointestinal disturbances, which often necessitate dose reduction, interruption, or permanent discontinuation. to overcome these challenges, the investigators address to the constrained disorder principle (cdp), an innovative approach that emphasizes the exploration of constrained variability in treatment regimens to optimize drug effectiveness and minimize aes. in other disease contexts, such as congestive heart failure, multiple sclerosis, and chronic pain, the integration of cdp-based second-generation artificial intelligence (ai) systems into treatment regimens has shown promising results in enhancing therapeutic outcomes by dynamically adjusting treatment parameters. the investigators hypothesize that a personalized dynamic adjustment of lenvatinib dosages and administration timing, guided by an ai-driven approach via a mobile application, may reduce aes, improve adherence, and enhance overall treatment efficacy. in this proof-of-concept study, the investigators aim to evaluate the feasibility and efficacy of utilizing a cdp-based second-generation ai system to optimize the therapeutic regimen of lenvatinib in patients with cancer.

Eligibility criteria:
inclusion criteria: 1. age 18-80 years 2. lenvatinib treated cancer patients, who suffer from loss of response of dose-limiting adverse effects. exclusion criteria: 1. current or history of drug abuse 2. pregnancy/lactation/planned pregnancy 3. the subject is currently enrolled in or has not yet completed at least 60 days since ending another investigational device or drug trial. 4. unable to comply with study requirements.

Keywords: cancer lenvatinib constrained disorder principle digital pill
study of cm310 injection in subjects with moderate-to-severe atopic dermatitis

Conditions: Atopic Dermatitis

Summary: this study is a multi-center, randomized, double-blind, parallel controlled phase 2 study, aimed at evaluating the efficacy and safety of cm310 in the treatment of patients with moderate-to-severe atopic dermatitis, and observing pharmacokinetics characteristics, pharmacodynamics effects and immunogenicity.

this study includes screening, treatment and follow-up periods. 160 subjects will be enrolled to receive cm310.

Eligibility criteria:
inclusion criteria: * have the ability to understand the study and voluntarily sign a written icf. * age ≥ 18 and ≤ 75 years old, male or female. * the fertile subjects agreed to take effective contraceptive measures throughout the study period. * the subjects can communicate well with the investigators and complete the follow-up according to the protocol. exclusion criteria: * live vaccine or attenuated live vaccine has been vaccinated or planned to be vaccinated within 12 weeks before randomization. * he received allergen-specific immunotherapy (desensitization therapy) within 6 months before randomization. * major surgery is planned during the study period. * previous history of atopic keratoconjunctivitis and corneal involvement. * other combined skin diseases that may affect the evaluation of the study. * confronting il-4r α monoclonal antibody or cm310/placebo drug or ingredient allergy.
eccentric versus concentric exercises for rotator cuff tendinopathy in patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis; Rotator Cuff Tendinosis; Tendinopathy

Summary: study aiming at determining the efficacy of eccentric versus concentric exercises for improving tendon biological characteristics, pain, and shoulder overall function for rotator cuff tendinopathy in patients with rheumatoid arthritis (ra). moreover, investigation the relationship between ra activity and the severity of rotator cuff tendinopathy. patients will be randomly assigned into either concentric or eccentric exercise group. randomizations will be done using computer random generated numbers.

study aiming at determining the efficacy of eccentric versus concentric exercises for improving tendon biological characteristics, pain, and shoulder overall function for rotator cuff tendinopathy in patients with ra. moreover, investigation the relationship between ra activity and the severity of rotator cuff tendinopathy. patients will be randomizations using computer random generated numbers. patients will receive either eccentric or concentric exercises for internal, external rotators and abductors muscles all patient will do stretching for posterior capsule and pectoralis minor tendon biological changes and subacromial space will be assessed using musculoskeletal ultrasonography shoulder function will be assessed using spadi (shoulder pain and disability index pain will be assessed using visual analogue scale (vas) rheumatoid arthritis disease activity will be assessed using disease activity score-28 for rheumatoid arthritis with erythrocyte sedimentation rate (das 28 esr) patient will be assessed at base-line and after finishing of the study

Eligibility criteria:
inclusion criteria: 1. adult patients diagnosed with ra according to 2010 (american college of rheumatology)(acr)/european league against rheumatism (eular) classification criteria for ra 2. patients diagnosed with rotator cuff tendinopathy based on clinical and musculoskeletal ultrasonography (msus) finding. 3. patient complaining of shoulder pain for at least 3 months 4. positive jobs test or hornblower sign or left off test 5. age ranged from 18 to 50 years. exclusion criteria: 1. patient indicated for surgical repair of rotator cuff 2. patient with previous shoulder surgery. 3. patient with history of intra-articular shoulder fracture. 4. patient with history of shoulder dislocation 5. diabetes mellitus
a study to evaluate the efficacy and safety of ak120 in the treatment of subjects with moderate-to-severe asthma

Conditions: Asthma

Summary: this is a randomized, double-blind, placebo-controlled, multicenter, phase ii clinical study to evaluate the efficacy and safety of ak120 in the treatment of subjects with moderate-to-severe asthma.

this is a randomized, double-blind, placebo-controlled, multicenter, phase ii clinical study. the purpose of this study is to evaluate the efficacy and safety of ak120 in the treatment of subjects with moderate-to-severe asthma and not adequately controlled with current stable medium-to-high-dose inhaled glucocorticoids plus up to two additional controllers.subjects will be randomized to receive ak120 or placebo subcutaneous injection.

Eligibility criteria:
key inclusion criteria: 1. male or female subjects aged ≥18 years old and ≤75 years old; 2. asthma was diagnosed ≥ 12 months before screening, current stable treatment with medium-to-high-dose inhaled glucocorticoids plus up to two additional controllers ≥ 3 months; 3. blood eosinophil≥ 200 cells per microliter within 6 months before screening; 4. during the screening, 40% of the predicted normal value \< pre-bronchodilator fev1 \< 80% of the predicted normal value, within 12 months before randomization, reversible airflow restriction was recorded; 5. asthma was inadequately controlled; 6. for women with childbearing potential, they are not pregnant or lactating, and the subjects and their partners voluntarily take effective contraceptive measures judged by the investigators during the treatment and at least 3 months after last dose. key exclusion criteria: 1. subjects with lung diseases other than asthma, which may affect the subject's health or end point evaluation of the study; 2. subjects had severe exacerbation events or systemic glucocorticoids usage within 1 month before randomization; 3. respiratory tract infection and any serious infection within 1 month before randomization; 4. subjects with parasitic infection, active tuberculosis infection, hepatitis b, hepatitis c, human immunodeficiency virus (hiv) or syphilis positive confirmation test; 5. known or suspected history of immunosuppression; 6. history of malignant tumors; 7. a history of smoking: those who had quit smoking for ≤ 6 months before screening, or smoking history \> 10 pack per year; 8. previous treatment with interleukin-4 (il-4) or interleukin-13 (il-13) inhibitors, and inadequate washout period of other biologic therapy; 9. allergen immunotherapy within 3 months before randomization; 10. progressive or uncontrolled other diseases or any other conditions or abnormal laboratory tests for which the investigator assess that the subjects are not suitable to enrol in the study.

Keywords: ak120 efficacy safety
sleep quality and amyloid-beta kinetics

Conditions: Amyloid-beta

Summary: the purpose of this study is to change the concentration of amyloid-beta in human cerebrospinal fluid (csf) by modification of sleep efficiency.

the purpose of the study is to investigate whether or not increasing sleep efficiency will change the concentration of amyloid-beta in cerebrospinal fluid (csf).

Eligibility criteria:
inclusion criteria: * age 45-65 years * any sex * any race/ethnicity * mini-mental status examination score (mmse) \>=27 * sleep efficiency measured by actigraphy to determine good sleeper or poor sleeper exclusion criteria: * cognitive impairment as determined by history of mmse \< 27 * inability to speak or understand english * bmi \>35 * any sleep disorders other than insomnia * history of sleep-disordered breathing * stop-bang score \> 3 * history or reported symptoms suggestive of restless legs syndrome, narcolepsy or other sleep disorders * sleep schedule outside the range of bedtime 8pm-12am and wake time 4am-9am * contraindication to lumbar catheter (anticoagulants; bleeding disorder; allergy to lidocaine or disinfectant; prior central nervous system or lower back surgery) * cardiovascular disease requiring medication except for controlled hypertension (pi discretion) * stroke * hepatic or renal impairment * pulmonary disease (pi discretion) * type 1 diabetes * hiv or aids * neurologic or psychiatric disorder requiring medication (pi discretion) * alcohol or tobacco use (pi discretion) * use of sedating medications * inability to get out of bed independently * abnormal movement of the non-dominant arm (would affect actigraphy data in unpredictable ways) * abnormal physical examination * current pregnancy * history of migraine headaches (pi discretion) * history of drug abuse in the past 6 months * urinary or fecal incontinence * difficulty sleeping in an unfamiliar environment (good sleep quality group only) * history or presence of any clinically significant medication condition, behavioral or psychiatric condition (including suicidal ideation), or surgical history based on medical record or patient report that could affect the safety of the subject or interfere with study assessments or in the judgment of the pi is not a good candidate
a pharmacist-led intervention to increase inhaler access and reduce hospital readmissions (pillar)

Conditions: COPD; Asthma

Summary: the goal of this study is to assess the impact of pharmacist-led benefits investigations and application of clinical practice guidelines on patient access to inhalers and time to hospital readmission or emergency department (ed) visit.


Eligibility criteria:
inclusion criteria: * adult patient admitted to vanderbilt university medical center (vumc) (excluding surgery services) * on a long acting inhaler or prescribed a long acting inhaler during admission. exclusion criteria: * diagnosis of cystic fibrosis * diagnosis of graft versus host disease (gvhd) * no medication insurance * discharge to any post-acute care facility or inpatient hospice * death during hospitalization

Keywords: inhaler pharmacy
identifying new biomarkers of parkinson's from routine brain imaging

Conditions: Parkinson Disease

Summary: the study will use routine computer tomography (ct), magnetic resonance spectroscopy (mri) and nuclear medicine (nm) brain imaging data to produce new diagnostic tests for the onset of parkinson's disease. this will enable hopefully earlier diagnosis than is currently possible. this will entail the analysis of anonymised ct/mri/nm brain images collected prior to the point when these subjects were diagnosed with pd.

we intend to use historical ct/mri/nuclear medicine brain scans to identify novel imaging biomarkers of prodromal parkinson's disease. the primary data source for the study will be mri and ct brain scans, whilst nuclear medicine imaging brain imaging (dat scans) will be used to validate models produced and provide a functional outcome measure of brain dopamine uptake. we shall utilise a an artificial intelligence approach to compare scans of pd cases with matched controls in order to identify these imaging biomarkers. a list of participants with a diagnosis will be compiled. this list, together with relevant clinical data, will be linked with historical ct/mri/nuclear medicine scans carried out over the preceding years. a control group of matched non-pd scans will also be compiled. the dataset will be anonymised and a bespoke ml pipeline will be used to identify imaging featureswhich may be indicative of prodromal pd. this initial stage will be carried out at university hospital plymouth nhs trust (uhpnt), the royal cornwall hospital nhs trust (rchnt) and cornwall partnership nhs trust (cpnt). if successful, findings will be validated in a larger sample of scans compiled from hospitals regionally and nationally.

Eligibility criteria:
inclusion criteria: - a clinical diagnosis of parkinson's exclusion criteria: - no clinical diagnosis of parkinson's
repetitive transcranial stimulation (rtms) for resistant depression in adolescents

Conditions: Adolescent Depression

Summary: the investigators hypothesis that repetitive transcranial stimulation (rtms) is a safe and effective add-on therapy for resistent depression in adolescent patients. a group of adolescents suffering from non psychotic major depression that was resistant to at least 2 drug trials and a trail of psychotherapy will be recruited. after an informed consent procedure for both parents and patients, patients will go through a clinical and cognitive evaluation. they will receive a protocol of 4 weeks (20 work days) of rtms using the figure of 8 magstim coil at 100% threshold, 42 trains of 4 seconds each, intertrain interval of 30 sec to the ldpc, 1680 pulses per day. then they will be reevaluated.


Eligibility criteria:
inclusion criteria: * age 15-18 years old * right hand dominant * suffering from major depression * cdrs \> 60 * at least 3 months of current depressive episode * failed 2 drug trials (or 3 drug trials if trial terminated prematurely due to side effects) and at least 1 course of psychotherapy * no contraindication for rtms (safety questionnaire) * no change in pharmacotherapy in the last month exclusion criteria: * schizophrenia or psychotic symptoms * hypertension * epilepsy * history of major head trauma * metal implements in the head * history of neurosurgery * history of severe head migraine * history of hearing loss or sp cochlear transplantation * pregnancy * current drug abuse * unstable medical condition * history of manic episode * current treatment with lithium or tricyclic or tetracyclic antidepressants

Keywords: adolescent resistant depression repetitive transcranial magnetic stimulation treatment of resistant adolescent depression
nicotine metabolizers and [11c]-(+)-phno

Conditions: Nicotine Dependence

Summary: the purpose of this study is to investigate the effects of nicotine metabolism on occupancy of \[11c\]-(+)-phno to da 2/3 receptors in different brain areas during periods of abstinence and smoking during an abstinence. this will be a positron emission tomography (pet) study and the radiotracer \[11c\]-(+)-phno (11c\]-( + )-4-propyl- 3,4,4a,5,6,10b-hexahydro-2h-naphtho\[1,2-b\]\[1,4\]oxazin-9-ol) will be used.

the participants will undergo a pet scan after approximately 48 hours abstinence (to ensure total elimination of nicotine in both fms and sms) and then approximately \>5 hours later may have a second pet scan after smoking their preferred cigarette (approximately 1 hour before). it is possible that these two scans may also occur on separate days. all subjects will provide a urine sample for (1) drug toxicology, (2) pregnancy test (in females) and (3) total nicotine equivalents (tne: a measure of total consumption unaltered by rate of nicotine metabolism). there will one blood draw taken before and one after each pet scan (about 20mls in total) to measure nicotine and cot levels (to assess abstinence) as well as kinetics of nicotine delivery. participants will be given questionnaires prior to, or during, and/or after one or both of the pet scans to determine differences between abstinence and smoking on subjective measures..

Eligibility criteria:
inclusion criteria: * males and females of any ethnic origin 18 years of age or older. * no previous use of medication for smoking cessation in previous month- * non-treatment seeker * either sms or fms by nmr exclusion criteria: * dsm-iv diagnosis of other drug dependences * any medical condition requiring immediate investigation or treatment * pregnancy tested by urine or lactation by self-report * current diagnosis of any axis i psychiatric disorder * regular use of any therapeutic or recreational psychoactive drug use that may interfere with pet scanning * exposure to radiation in the last 12 months exceding permissible limit for participants participating in research * current use of medication that may interfere with \[11c\]-(+)-phno * metal implants or paramagnetic objects within the body which may interfere with the mri * claustrophobia or a history of panic attacks * having any clinical condition, drug sensitivity, or prior therapy which, in the investigator's opinion, makes the participant unsuitable for the study * current use of antidepressants that may inhibit cyp2a6 or impact response to nicotine